CEOCFO Magazine Interviewed Aclipse Therapeutics CEO Raymond Houck

Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia

KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has

November 10, 2024

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

Aclipse Therapeutics Announces Publication in Nature Reviews Drug Discovery of an Amyotrophic Lateral Sclerosis Review including M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – January 2, 2023 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

January 2, 2023

Aclipse Therapeutics Announces Issuance of Composition-of-Matter Patent for M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – November 10, 2022 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

November 10, 2022

March 11, 2021

CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He has also described the target pathomechanisms of M102 and its precision medicine approach to ALS and CNS diseases.

Learn More